Here we describe a patient with ALK-fusion positive widely metastatic salivary ductal carcinoma, who achieved a durable complete response from alectinib, a potent and specific ALK tyrosine kinase inhibitor...She also had a PET-CT scan that showed metastatic disease and her tissue was sent to Strata Oncology...which identified an EML4-ALK fusion. The patient was started on an ALK inhibitor, alectinib, and had complete resolution of her cancer which is ongoing at eight months.